Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Trade Rep Cuts 22 China-Made Devices From Tariffs List, But Retains 27

Executive Summary

While the Trump administration appears to have been partially persuaded by industry arguments that a host of China-made medtech items do not belong on a list of items earmarked for a 25% tariff starting July 6, there are still 27 devices – or accessories – that remain.

You may also be interested in...

Industry Groups Oppose 25% China Tariffs Still In Play On High-End Medical Equipment, Hospital Products

Industry groups expressed strong opposition at the end of June to US-planned 25% tariffs on China goods – including billions of dollars in medtech and hospital supplies – by the US Trade Representative’s Office, despite ongoing talks between President Trump and Chinese President Xi Jinping to deal with US-China trade tensions.

US Starts Imposing China Medtech Tariffs, But Offers Path To Product Exclusions

Although the 25% tariffs initiated July 6 by the US Trade Representative will impact about $836m worth of medical technology entering the US from China, the administration late last week offered a process for gaining exclusions for specific products. AdvaMed members are “looking into” the process, the group said, and Medical Imaging and Technology Alliance members have already started to try to use it.

Industry Gives US Trade Rep 12 Reasons Why Tariffs on Chinese Medtech Imports Are A Bad Idea

The US Trade Representative office's decision in March to include devices, imaging machines and diagnostics on a list of Chinese imports destined for a 25% tariff has riled up the industry. A half-dozen medtech organizations protested the move in comments and testimony this week, supplying USTR with 12 reasons why the tariffs are a very bad idea.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts